Literature DB >> 18174770

Patterns and associated health services costs of antihypertensive drug modifications.

Shadi S Saleh1, Steven Szebenyi, Judith A Carter, Chris Zacher, Dan Belletti.   

Abstract

This study sought to identify patterns of antihypertensive drug modifications in initial drug therapy as well as to examine the effect of modifications on costs. The study population included adults who initiated antihypertensive drug therapy during 12 months of therapy. Approximately three-fourths of study participants had a change in therapy within the first 12 months of treatment. Discontinuation (57.1%) of antihypertensive drug treatment was the most prevalent modification type, followed by titrations (14.6%). Initiating treatment with fixed-dose combinations was associated with the lowest likelihood of a nondiscontinuation modification (12.5%); the use of 2 separate drugs was associated with the least likelihood of complete discontinuation (28.7%). The presence of therapy changes was associated with increased health services costs in the first 12 months of antihypertensive drug therapy. Clinicians and payers should be aware of the association between starting specific antihypertensive treatment regimens and the likelihood of changes in medication and changing costs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174770      PMCID: PMC8109876          DOI: 10.1111/j.1524-6175.2007.07307.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  17 in total

Review 1.  Overcoming barriers to effective blood pressure control in patients with hypertension.

Authors:  Rainer Düsing
Journal:  Curr Med Res Opin       Date:  2006-08       Impact factor: 2.580

Review 2.  Fixed low-dose combination in first-line treatment of hypertension.

Authors:  L Michael Prisant
Journal:  J Hypertens Suppl       Date:  2002-02

3.  Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications.

Authors:  Jerome Wilson; Kirsten Axelsen; Simon Tang
Journal:  Am J Manag Care       Date:  2005-01       Impact factor: 2.229

4.  Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus.

Authors:  Nicolas Rodondi; Tiffany Peng; Andrew J Karter; Douglas C Bauer; Eric Vittinghoff; Simon Tang; Daniel Pettitt; Eve A Kerr; Joe V Selby
Journal:  Ann Intern Med       Date:  2006-04-04       Impact factor: 25.391

5.  Initiation of hypertension treatment with a fixed-dose combination or its monocomponents -- does it really matter?

Authors:  J Scholze; M Bida; A Hansen; D Juncken; B Rangoonwala; A Ritz; J Schnitker; Y Dörffel
Journal:  Int J Clin Pract       Date:  2006-03       Impact factor: 2.503

6.  Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991.

Authors:  V L Burt; J A Cutler; M Higgins; M J Horan; D Labarthe; P Whelton; C Brown; E J Roccella
Journal:  Hypertension       Date:  1995-07       Impact factor: 10.190

7.  Improving hypertension care in a large group-model MCO.

Authors:  Paul Godley; Anh Nguyen; Krista Yokoyama; James Rohack; Billy Woodward; Tina Chiang
Journal:  Am J Health Syst Pharm       Date:  2003-03-15       Impact factor: 2.637

Review 8.  Hypertension--a treatable component of the cardiometabolic syndrome: challenges for the primary care physician.

Authors:  Camila M Manrique; Guido Lastra; John Palmer; Craig S Stump; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

Review 9.  The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression.

Authors:  William C Cushman
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

Review 10.  Management strategies for patients with hypertension and diabetes: why combination therapy is critical.

Authors:  Sara Giunti; Mark Cooper
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-02       Impact factor: 3.738

View more
  3 in total

1.  Persistence to antihypertensive drug treatment in Swedish primary healthcare.

Authors:  Miriam Qvarnström; Thomas Kahan; Helle Kieler; Lena Brandt; Jan Hasselström; Kristina Bengtsson Boström; Karin Manhem; Per Hjerpe; Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2013-07-16       Impact factor: 2.953

2.  Achieving Adherence After First-Line Antihypertensive Treatment: Should Fixed-Dose Combinations Receive Priority?

Authors:  Kalyani B Sonawane Deshmukh; Jingjing Qian; Kimberly B Garza; Bradley M Wright; Peng Zeng; Cecilia M Ganduglia Cazaban; Richard A Hansen
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-02-24       Impact factor: 3.738

3.  Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals.

Authors:  Jan Basile
Journal:  Integr Blood Press Control       Date:  2010-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.